Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical features (1; 2). SLE manifestations are associated with multiple autoantibodies, ensuing immune complex formation and deposition, and other immune processes (2; 3).

2024年1月2日 · HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and ...

2023年10月11日 · Objectives To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed the questions for the systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation of the statements after a series of meetings.

ANA = antinuclear antibodies; anti-dsDNA = anti–double-stranded (ds) DNA; EULAR/ACR = European League Against Rheumatism/American College of Rheumatology; SLE = systemic lupus erythematosus. Data from Aringer M, Costenbader K, Daikh D, et al : 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for ...

2023年10月13日 · The 2023 updates provide 5 overarching principles and 13 recommendations to guide physicians treating lupus around the world.

Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight.

To assess the sensitivity and specificity of the 2019 EULAR/American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in outpatients at an academic tertiary care centre and to compare them to the 1997 ACR and the 2012 Systemic Lupus International Collaborating Clinics criteria.

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical features (1;2). SLE manifestations are associated with multiple autoantibodies, ensuing immune complex formation and deposition, and other immune processes (2;3).

The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) have become a ‘tradition’ since their first publication in 2008, guiding physicians who care after patients with this challenging disease.

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical features. 1 2 SLE manifestations are associated with multiple autoantibodies, ensuing immune complex formation and deposition, and other immune processes. 2 3 This complex clinical presentation and pathogenesis makes SLE a difficult disease to grasp and def...